Astrazeneca Pharma India Ltd. (BSE: 506820) is a Bengaluru, Karnataka-based company in the Pharmaceuticals industry. With a market capitalisation of ₹14,970 Cr, it ranks #427 by market cap among the 6,189 Indian listed companies on FinBizNet, and #9 of 63 in Pharmaceuticals. At ₹5,988.15 (as of 26 Oct 2026), the share price is 39.2% below its 52-week high of ₹9,849.50 and 6.2% above its 52-week low of ₹5,640.00. The share price is down 34.5% over one year and down 25.2% over three months.
| Current Price | ₹5,988.15 |
|---|---|
| Market Cap | ₹14,970 Cr |
| BSE Code | 506820 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 79.8 |
| Return on Equity | 22.82% |
| Return on Assets | 8.33% |
| 52-Week Range | ₹5,640.00 – ₹9,849.50 |
| 1-Year Price Change | -34.5% |
| 3-Month Price Change | -25.2% |
| Beta (1Y) | 0.35 |
| Dividend Yield | 0.60% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.astrazeneca.in |
| Revenue | ₹683 Cr |
|---|---|
| Net Profit | ₹38 Cr |
| Net Margin | 5.6% |
| EPS (Basic) | ₹15.17 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
1. Segment Adjustment-This segment manufactures, markets, and distributes pharmaceutical products; and provides clinical trial services. 2. Healthcare-0 3. Others-This segment provides clinical trial services on pharmaceutical products. 4. Unallocated Assets-0
1. Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹53,132 Cr | 34.2 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,028 Cr | 38.9 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹33,581 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹25,398 Cr | -77.7 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹23,578 Cr | 93 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹16,891 Cr | 26.4 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹16,525 Cr | 22.9 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,199 Cr | 24.2 | 18.07% | ₹873 Cr | -30.8% |
| Astrazeneca Pharma India Ltd. | ₹14,970 Cr | 79.8 | 22.82% | ₹683 Cr | -34.5% |
Listed by market capitalisation. Ratios are shown for context only.
Astrazeneca Pharma India Ltd. is trading at ₹5,988.15, with a market capitalisation of ₹14,970 Cr.
Astrazeneca Pharma India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Astrazeneca Pharma India Ltd. has a P/E of 79.8 and a return on equity of 22.82%.
Astrazeneca Pharma India Ltd. is listed on the BSE under the scrip code 506820.
Astrazeneca Pharma India Ltd.'s share price is down 34.5% over one year and down 25.2% over three months. Its 52-week range is ₹5,640.00 to ₹9,849.50.
In Q1 FY27, Astrazeneca Pharma India Ltd. reported revenue of ₹683 Cr and net profit of ₹38 Cr, with basic EPS of ₹15.17 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.